Log in
Enquire now
‌

US Patent 8754065 Tenofovir alafenamide hemifumarate

Patent 8754065 was granted and assigned to Gilead Sciences on June, 2014 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
Gilead Sciences
Gilead Sciences
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
8754065
Patent Inventor Names
Dazhan Liu0
Bing Shi0
Fang Wang0
Richard Hung Chiu Yu0
Date of Patent
June 17, 2014
Patent Application Number
13586358
Date Filed
August 15, 2012
Patent Citations Received
‌
US Patent 12122765 Methods and intermediates for preparing therapeutic compounds
0
‌
US Patent 11760746 Methods and intermediates for preparing therapeutic compounds
‌
US Patent 11787825 Therapeutic compounds for HIV virus infection
‌
US Patent 11833143 Choline salt forms of an HIV capsid inhibitor
0
‌
US Patent 11944611 Capsid inhibitors for the treatment of HIV
0
‌
US Patent 11993583 Therapeutic compounds
0
‌
US Patent 12077537 Capsid inhibitors for the treatment of HIV
0
‌
US Patent 12084467 Therapeutic compounds for HIV virus infection
0
...
Patent Primary Examiner
‌
James D. Anderson
No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 8754065 Tenofovir alafenamide hemifumarate

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.